

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	1
STUDY GOALS AND OBJECTIVES	1
REASONS FOR DOING THE STUDY	1
SCOPE AND FORMAT	2
INTENDED AUDIENCE	2
METHODOLOGY	2
RELATED BCC STUDIES	3
ANALYST CREDENTIALS	3
BCC ON-LINE SERVICES	3
DISCLAIMER	3
CHAPTER 2 SUMMARY	5
<i>SUMMARY TABLE GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, THROUGH 2016 (\$ MILLIONS)</i>	6
<i>SUMMARY FIGURE GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, 2010-2016 (\$ MILLIONS)</i>	6
CHAPTER 3 OVERVIEW	9
BREAST CANCER DIAGNOSTICS AND TRENDS	9
BREAST CANCER	9
EARLY BREAST CANCER DETECTION	9
<i>TABLE 1 POSSIBLE SIGNS OF BREAST CANCER</i>	10
IMAGING TESTS	10
MAMMOGRAPHY	10
DIAGNOSTIC MAMMOGRAMS	10
<i>TABLE 2 DIAGNOSTIC MAMMOGRAM FOR BREAST CANCER</i>	11
DIGITAL MAMMOGRAMS	11
Usefulness of Mammography	11
MAGNETIC RESONANCE IMAGING OF THE BREAST	12
BREAST ULTRASOUND	12
DUCTAL LAVAGE AND NIPPLE ASPIRATION	12
BIOPSY	13
Fine Needle Aspiration Biopsy	13
Core Needle Biopsy	13
Vacuum-Assisted Biopsies	14
Surgical (Open) Biopsy	14
LYMPH NODE DISSECTION AND SENTINEL LYMPH NODE BIOPSY	14
Laboratory Examination	14
TYPES OF BREAST CANCER	14
<i>TABLE 3 BREAST CANCER GRADES</i>	15
DUCTAL CARCINOMA IN SITU	15
ESTROGEN RECEPTOR AND PROGESTERONE RECEPTOR STATUS	15
HER2/NEU STATUS	16
<i>TABLE 4 BIOPSY OR SURGERY SAMPLE TESTING</i>	16
GENE EXPRESSION PROFILING	17
<i>TABLE 5 TESTS USED TO EVALUATE DIFFERENT GENE SETS</i>	17

<b>TOPIC</b>	<b>PAGE NO.</b>
Test Usefulness	17
Imaging Tests to Determine if Breast Cancer Has Spread	17
<i>Table 6 IMAGING TESTS THAT DETERMINE IF BREAST CANCER HAS SPREAD</i>	18
THE FUTURE OF BREAST CANCER DETECTION	18
DIAGNOSTIC TESTS AND THEIR VALUE IN BREAST CANCER TESTING	18
<i>TABLE 7 HER2 TESTING AND VARIATIONS</i>	19
NEED FOR BREAST CANCER SCREENING	22
OVERDIAGNOSIS	23
Diagnosis and Treatment Regimen	23
GUIDELINES FOR BREAST CANCER DETECTION	24
<i>TABLE 8 GUIDELINES FOR EARLY DETECTION OF BREAST CANCER IN AVERAGE RISK, ASYMPTOMATIC WOMEN</i>	25
Breast Cancer Screening Recommendations	25
USPSTF BREAST CANCER SCREENING GUIDELINES	26
<i>TABLE 9 BREAST CANCER SCREENING RECOMMENDATIONS BY THE USPSTF</i>	26
CHAPTER 4 BIOMARKERS AND DEVELOPMENT OF CANCER DIAGNOSTICS	29
BIOMARKERS AND CANCER	29
BIOMARKERS AND BREAST CANCER	29
<i>TABLE 10 BREAST CANCER PROGNOSTIC FACTORS</i>	30
<i>TABLE 11 BREAST CANCER PREDICTIVE FACTORS</i>	30
<i>TABLE 12 RECURRENCE RATES AT FIVE YEARS IN PATIENTS WITH LYMPH NODES THAT ARE POSITIVE FOR CANCER (%)</i>	31
<i>TABLE 13 FIVE-YEAR SURVIVAL RATES CORRELATED WITH TUMOR STAGE (%)</i>	31
HER2	31
COMPANION DIAGNOSTICS	32
TARGETED THERAPIES	32
PREDICTIVE DIAGNOSTICS	32
<i>TABLE 14 PREDICTIVE DIAGNOSTIC FEATURES</i>	32
PREDICTIVE SAFETY BIOMARKERS	33
Commercialized Biomarker Tests	33
<i>Table 15 CURRENT BIOMARKER TECHNOLOGIES</i>	34
<i>Table 16 BIOMARKER USES</i>	35
BIOMARKERS AND DRUG THERAPY	35
INCREASED USE OF BIOMARKERS IN DRUG DEVELOPMENT AND CLINICAL TRIALS	36
OBSTACLES TO BIOMARKER DEVELOPMENT	36
<i>TABLE 17 MAJOR ISSUES AND CHALLENGES</i>	36
BIOMARKERS TYPES	37
Predictive Biomarkers	37
Tumor Interstitial Fluid Biomarkers	37
Pharmacogenomic Biomarkers in Drug Labels	38
BENEFITS OF PHARMACOGENOMICS	38
<i>TABLE 18 PHARMACOGENOMICS TESTS IN USE</i>	39
BARRIERS TO PHARMACOGENOMICS PROGRESS	39
Biomarkers in Drug Labels	39
CLASSIFICATION OF BIOMARKERS	40
<i>TABLE 19 BIOMARKERS FOR DRUG LABELS BASED ON SPECIFIC USE</i>	40
<i>TABLE 20 CANCER BIOMARKERS FOR FDA-MANDATED TESTING PRIOR TO DRUG USE</i>	40

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 21 CLINICALLY RELEVANT BIOMARKERS</i>	40
FDA GUIDANCE	41
<i>TABLE 22 APPROVED COMPANION DIAGNOSTICS, 2011</i>	41
COMPANION DIAGNOSTICS AND SEVERAL REGULATORY ISSUES	43
<i>TABLE 23 REGULATORY APPROVAL OF THE DIAGNOSTICS PATHWAY</i>	44
FDA Route	44
CLIA-Based (Laboratory-Developed Tests) Route	44
CHOOSING A REGULATORY PATHWAY	45
A Co-Development Path	45
Issues and Barriers to Development	46
Drug Approval in 2011	46
<i>Table 24 APPROVED CANCER DRUGS, 2011</i>	47
Post-Launch Expectations	47
Dako's EGFR Immunohistochemistry Assay	47
Role of Reimbursement Bodies	48
Considerations for New Drug—Diagnostic Partnerships	48
<i>Table 25 FACTORS INFLUENCING THE CHOICE OF A DIAGNOSTICS PARTNER</i>	48
HercepTest and Trastuzumab (Herceptin)	48
NEXT STEPS	49
CHAPTER 5 BREAST CANCER	51
SYNOPSIS	51
<i>TABLE 26 SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS SUMMARY STAGE SYSTEM FOR BREAST CANCER</i>	52
CLASSIFICATION OF BREAST CANCER	52
<i>TABLE 27 MAIN TYPES OF BREAST CANCER</i>	52
Luminal A and Luminal B Types	53
HER2 Type	53
Basal Type	53
TRIPLE-NEGATIVE BREAST CANCER TREATMENTS IN THE PIPELINE	54
CAUSES, INCIDENCE AND RISK FACTORS	54
Symptoms	55
<i>Table 28 BREAST CANCER EVALUATION TESTS</i>	55
BREAST CANCER CAUSES	56
PATHOPHYSIOLOGY	56
TREATMENT	56
<i>TABLE 29 TREATMENT PLAN</i>	56
<i>TABLE 30 HORMONE THERAPY</i>	57
Cancer Treatment: Local or Systemic	57
<i>Table 31 CANCER STAGES</i>	57
PROGNOSIS AFTER TREATMENT	58
<i>TABLE 32 RISK FACTORS OF RECURRENCE AFTER SUCCESSFUL TREATMENT FOR BREAST CANCER</i>	58
BREAST CANCER TREATMENT GUIDELINES	58
Prevention	59
<i>Table 33 BREAST CANCER PREVENTION MEASURES</i>	59
<i>Table 34 AMERICAN CANCER SOCIETY'S DIETARY GUIDELINES FOR CANCER PREVENTION</i>	59

TOPIC	PAGE NO.
CHAPTER 6 BREAST CANCER PREVALENCE AND INCIDENCE RATES	61
CANCER INCIDENCE ACROSS THE GLOBE	61
BREAST CANCER GLOBALLY	61
GLOBAL BREAST CANCER STATISTICS	62
TABLE 35 BREAST CANCER INCIDENCE AND MORTALITY GLOBALLY, 2008 (THOUSANDS)	63
FIGURE 1 GLOBAL BREAST CANCER INCIDENCE AND MORTALITY, 2008 (THOUSANDS)	63
GEOGRAPHIC VARIATION IN BREAST CANCER RATES	64
TABLE 36 ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2010-2016	65
FIGURE 2 ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2010-2016	65
TABLE 37 NEW BREAST CANCER CASES BY GEOGRAPHIC REGION, 2009 (THOUSANDS/%)	66
HIGHEST INCIDENCE RATES GLOBALLY	67
TABLE 38 EFFECTIVE EDUCATION AND SCREENING ADVANTAGES IN THE U.K. AND THE U.S. (CASES PER DAY)	67
EUROPE	68
U.K.	68
Table 39 CRUDE AND EUROPEAN AGE-STANDARDIZED BREAST CANCER INCIDENCE RATES PER 100,000 POPULATIONS IN THE U.K., 2008	68
Table 40 U.K. ESTIMATED INCIDENCE OF BREAST CANCER, 2010-2016 (THOUSANDS)	68
FIGURE 3 U.K. ESTIMATED INCIDENCE OF BREAST CANCER, 2010-2016 (THOUSANDS)	68
Germany	69
Table 41 GERMAN ESTIMATED INCIDENCE OF BREAST CANCER AND PROJECTIONS, 2010-2016 (THOUSANDS)	69
FIGURE 4 GERMAN ESTIMATED INCIDENCE OF BREAST CANCER, 2010-2016 (THOUSANDS)	70
ASIA	70
CHINA	70
TABLE 42 CHINESE ESTIMATED INCIDENCE OF BREAST CANCER, 2008-2016 (THOUSANDS)	71
FIGURE 5 CHINESE ESTIMATED INCIDENCE OF BREAST CANCER, 2010-2016 (THOUSANDS)	71
INDIA	71
Table 43 INDIA ESTIMATED INCIDENCE OF BREAST CANCER, 2008-2016 (THOUSANDS)	72
FIGURE 6 INDIA ESTIMATED INCIDENCE OF BREAST CANCER, 2010-2016 (THOUSANDS)	72
JAPAN	73
Table 44 JAPAN ESTIMATED INCIDENCE OF BREAST CANCER, 2010 (THOUSANDS)	73
DEVELOPING COUNTRIES	73
Table 45 FIVE-YEAR SURVIVAL FOR BREAST CANCER (%)	74
Table 46 BREAST CANCER FIVE-YEAR SURVIVAL BY CANCER STAGE (%)	75
LOW-INCOME COUNTRIES	75
MIDDLE-INCOME COUNTRIES	75
U.S.	76
U.S. Breast Cancer Incidence, 2011	77
Table 47 U.S. ESTIMATED INCIDENCE OF BREAST CANCER, 2010-2016 (THOUSANDS)	77
FIGURE 7 U.S. ESTIMATED INCIDENCE OF BREAST CANCER, 2010-2016 (THOUSANDS)	77
Historical Data	78
Table 48 U.S. ESTIMATED NEW FEMALE BREAST CANCER CASES AND DEATHS BY AGE, 2011 (THOUSANDS)	78
2010 Breast Cancer Estimates	79
Table 49 U.S. ESTIMATED INCIDENCE OF BREAST CANCER, 2012 (THOUSANDS)	79
Men	79

TOPIC	PAGE NO.
<i>Table 50 COMPARISON OF BREAST CANCER INCIDENCE AND DEATH IN MEN AND WOMEN, 2012</i>	79
<i>Table 51 ESTIMATED BREAST CANCER INCIDENCE, 2004-2008, AND MORTALITY, 2003-2007 (THOUSANDS)</i>	81
<i>Table 52 BREAST CANCER ESTIMATES IN ASIAN WOMEN, INCIDENCE, 2004-2008, AND MORTALITY, 2003-2007 (PER 100,000)</i>	81
<i>Table 53 ESTIMATED BREAST CANCER INCIDENCE IN HISPANIC AND LATINA WOMEN, 2004-2008, AND MORTALITY, 2003-2007 (PER 100,000)</i>	82
AGE AND BREAST CANCER	82
<i>TABLE 54 BREAST CANCER RISK WITH AGE</i>	83
Breast Cancer and Race in the U.S.	83
<i>Table 55 U.S. RATES, TRENDS AND CAUSE-SPECIFIC SURVIVAL FOR FEMALE BREAST CANCER PATIENTS BY RACE OR ETHNICITY, 2001-2007</i>	83
In situ Breast Cancer	84
Invasive Breast Cancer	84
Initiative Randomized Trial Results	85
Incidence Trends by Race and Tumor Size	85
Incidence and Mortality Trends for Male Breast Cancer	85
Factors Influencing Breast Cancer Survival	86
<i>Table 56 RELATIVE CANCER SURVIVAL IN WOMEN</i>	86
Obesity, Physical Activity and Diet	86
TUMOR CHARACTERISTICS	86
AGE AT DIAGNOSIS	87
FAMILY HISTORY OF BREAST CANCER AND GENETIC PREDISPOSITION	87
HISTORICAL FACTS	88
CANADA	89
Estimated Number of New Cases	89
<i>Table 57 CANADA ESTIMATED NUMBER OF NEW BREAST CANCER CASES IN FEMALES BY AGE, 2010 (THOUSANDS)</i>	89
AUSTRALIA	90
<i>TABLE 58 AUSTRALIA PROJECTED NEW CASES OF BREAST CANCER, 2011-2021</i>	90
CHAPTER 7 BREAST CANCER DRUGS AND MARKET TRENDS	92
CLINICAL DIAGNOSIS AND MANAGEMENT	92
<i>TABLE 59 APPROVED ONCOLOGY DRUGS, 2012</i>	92
<i>TABLE 60 APPROVED ONCOLOGY DRUGS, 2011</i>	93
<i>TABLE 61 APPROVED ONCOLOGY DRUGS, 2010</i>	93
CANCER DRUGS AND MARKET TRENDS	94
INNOVATIONS IN THE BREAST CANCER THERAPEUTIC MARKET	94
BREAST CANCER AND DRUGS	94
EMERGING DIAGNOSTICS FOR CANCER DRUGS	95
TRIPLE NEGATIVE BREAST CANCER	96
POLY ADP RIBOSE POLYMERASE INHIBITORS	96
DRUGS APPROVED FOR BREAST CANCER	96
<i>TABLE 62 DRUGS APPROVED FOR BREAST CANCER</i>	97
MEDICINES FOR TREATING BREAST CANCER	98
Hormone Therapy	98
<i>Table 63 HORMONE THERAPY FOR BREAST CANCER</i>	98
<i>Table 64 AROMATASE INHIBITORS FOR TREATING BREAST CANCER</i>	99

<b>TOPIC</b>	<b>PAGE NO.</b>
Chemotherapy	99
<i>Table 65 CHEMOTHERAPY DRUGS FOR TREATING BREAST CANCER</i>	99
<i>Table 66 COMMONLY USED COMBINATIONS</i>	99
Medicines to Control Nausea and Vomiting	100
<i>Table 67 MEDICINES TO CONTROL AND PREVENT NAUSEA AND VOMITING</i>	100
TARGETED CANCER DRUG MARKET	100
<i>TABLE 68 MARKET FOR TARGETED CANCER DRUGS, 2008 AND 2016 (\$ MILLIONS)</i>	100
TARGETED THERAPIES FOR BREAST CANCER	100
Trastuzumab (Herceptin)	101
Pertuzumab	101
Lapatinib	101
<i>Table 69 TARGETED THERAPUTICS FOR BREAST CANCER</i>	102
Treatments for Breast Cancer with Low HER2 Expression	102
GLOBAL PHARMACEUTICAL MARKET	102
<i>TABLE 70 GLOBAL PHARMACEUTICAL SALES, THROUGH 2016 (\$ MILLIONS)</i>	103
<i>FIGURE 8 GLOBAL PHARMACEUTICAL SALES, 2010-2016 (\$ MILLIONS)</i>	103
CURRENT BREAST CANCER MARKET TRENDS	104
BREAST CANCER MARKET	105
<i>TABLE 71 BREAST CANCER THERAPY SALES, THROUGH 2016 (\$ MILLIONS)</i>	106
<i>FIGURE 9 BREAST CANCER THERAPY SALES, 2010-2016 (\$ MILLIONS)</i>	106
<i>TABLE 72 BREAST CANCER DRUG MARKET, 2010 AND 2016 (\$ MILLIONS)</i>	106
<i>FIGURE 10 BREAST CANCER DRUG MARKET, 2010 AND 2016 (\$ MILLIONS)</i>	107
<i>TABLE 73 AROMATASE INHIBITORS MARKET, 2010 AND 2016 (\$ MILLIONS)</i>	107
Targeted Therapies	107
<i>Table 74 BREAST CANCER TARGETED THERAPIES, 2010 AND 2011 (\$ MILLIONS)</i>	108
<i>Table 75 ROCHE SALES COMPARED TO THE GLOBAL MARKET, 2010 (\$ MILLIONS/%)</i>	108
<i>Table 76 XELODA SALES, 2010 AND 2011 (\$ MILLIONS)</i>	109
<i>Table 77 ROCHE-SALES VERSUS THE GLOBAL MARKET, 2011 (\$ MILLIONS/%)</i>	110
NEW MEDICINES FOR BREAST CANCER	110
<i>TABLE 78 EXPECTED SALES FOR PERTUZUMAB, 2016 (\$ MILLIONS)</i>	111
AUSTRALIA	111
<i>TABLE 79 CANCER THERAPY SALES, 2008 AND 2018 (\$ MILLIONS)</i>	112
<i>TABLE 80 AUSTRALIA TARGETED CANCER THERAPY SALES, 2008 AND 2018 (\$ MILLIONS)</i>	112
BREAST CANCER DRUGS AND INDIA	112
CHINA	113
EUROPE	113
CONCLUSIONS	113
CHAPTER 8 BREAST CANCER PREDICTIVE DIAGNOSTICS MARKET	115
CANCER COSTS PROJECTED TO REACH AT LEAST \$158 BILLION IN 2020	115
CANCER DRUG MARKET	115
<i>TABLE 81 ANTINEOPLASTIC MABS MARKET, 2008 AND 2014 (\$ MILLIONS)</i>	116
U.S. PERSONALIZED MEDICINE MARKET SIZE	116
<i>TABLE 82 U.S. PERSONALIZED MEDICINE MARKET, THROUGH 2016 (\$ MILLIONS)</i>	117
<i>FIGURE 11 U.S. PERSONALIZED MEDICINE MARKET, 2010-2016 (\$ MILLIONS)</i>	117
<i>TABLE 83 U.S. PERSONALIZED MEDICINE DIAGNOSTIC TESTS AND TARGETED THERAPIES MARKET, THROUGH 2016 (\$ MILLIONS)</i>	118

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 12 U.S. PERSONALIZED MEDICINE DIAGNOSTIC TESTS AND TARGETED THERAPIES MARKET, 2010-2016 (\$ MILLIONS)</i>	118
PERSONALIZED MEDICINE AND ISSUES	118
FACTORS INFLUENCING THE MARKET GROWTH AND INDUSTRY SPECIFIC CHALLENGES	119
<i>TABLE 84 GLOBAL MOLECULAR DIAGNOSTICS MARKET, THROUGH 2016 (\$MILLIONS)</i>	119
U.S. Molecular-Based Cancer Tissue Diagnostics	119
In Vitro Diagnostics	120
Major Market Drivers and Restraints	121
<i>Table 85 GLOBAL IVD MARKET, THROUGH 2016 (\$MILLIONS)</i>	121
BREAST CANCER DRUG MARKET	121
BREAST CANCER TESTING MARKET	121
NEXT-GENERATION CANCER DIAGNOSTICS	122
<i>TABLE 86 NEXT-GENERATION CANCER DIAGNOSTIC PRODUCTS BY TYPE, THROUGH 2016 (\$ MILLIONS)</i>	122
<i>FIGURE 13 NEXT-GENERATION CANCER DIAGNOSTIC PRODUCTS BY TYPE, 2010-2016 (\$ MILLIONS)</i>	122
GLOBAL MARKET AND TRENDS	123
<i>TABLE 87 ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2010-2016 (\$ THOUSANDS)</i>	123
<i>TABLE 88 GLOBAL INCIDENCE OF ESTROGEN RECEPTOR POSITIVE BREAST CANCER CASES, 2010-2016 (\$ THOUSANDS)</i>	124
GLOBAL MAMMOGRAPHY EQUIPMENT MARKET	125
Breast Biopsy Market	126
Molecular Diagnostics	127
COMPANION DIAGNOSTICS	127
PREDICTIVE TECHNOLOGY AND BREST CANCER MARKET TRENDS	127
<i>TABLE 89 PREDICTIVE TECHNOLOGY</i>	128
RELEVANT TESTS FOR BREAST CANCER PROGNOSIS	128
HER2	128
Gene Expression Profiling Tests	128
IHC4 Test	129
<i>Table 90 BREAST CANCER DIAGNOSTIC TEST COSTS</i>	130
<i>Table 91 GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC TECHNOLOGIES, THROUGH 2016 (\$ MILLIONS)</i>	131
<i>FIGURE 14 GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC TECHNOLOGIES, 2010-2016 (\$ MILLIONS)</i>	131
IHC AND FISH-BASED TESTS AND MARKET	131
<i>TABLE 92 IHC AND FISH-BASED BREAST CANCER TESTING SALES, THROUGH 2016 (\$ MILLIONS)</i>	132
<i>FIGURE 15 IHC AND FISH-BASED BREAST CANCER TESTING SALES, 2010-2012 (\$ MILLIONS)</i>	132
TISSUE-BASED IMMUNOHISTOCHEMISTRY MARKET	133
<i>TABLE 93 FDA-APPROVED COMMERCIAL KITS</i>	133
Hercep Test Kits	134
<i>Table 94 FDA-APPROVED FISH ANALYSIS TESTS</i>	135
KEY COMPANYIES	136
ROCHE	136
<i>TABLE 95 ROCHE SALES BY DIVISION, 2010 (\$ MILLIONS)</i>	137
<i>TABLE 96 ROCHE COMPANION DIAGNOSTICS CURRENTLY ON THE MARKET OR IN LATE DEVELOPMENT FOR BREAST CANCER</i>	137

TOPIC	PAGE NO.
DAKO	138
GENOMIC ASSAYS	138
TABLE 97 GENOMIC MARKET LEADERS	138
TABLE 98 GENOMIC TESTING MARKET FOR BREAST CANCER, THROUGH 2016 (\$ MILLIONS)	139
FIGURE 16 GENOMIC TESTING MARKET FOR BREAST CANCER, 2010-2016 (\$ MILLIONS)	139
GENOMIC HEALTH BUSINESS PROGRESS	140
TABLE 99 ONCOTYPE DX SALES, THROUGH 2016 (\$ MILLIONS)	140
Mammaprint Assay	140
Quantitative Fluorescence-Based Tests	141
Table 100 QUANTITATIVE FLUORESCENCE DIAGNOSTIC TESTING MARKET FOR BREAST CANCER, THROUGH 2016 (\$ MILLIONS)	142
FIGURE 17 QUANTITATIVE FLUORESCENCE DIAGNOSTIC TESTING MARKET FOR BREAST CANCER, 2010-2016 (\$ MILLIONS)	142
CONCLUSIONS	144
CHAPTER 9 COMPANY PROFILES	146
ABBOTT LABORATORIES	146
AETERNA ZENTARIS	147
AGENDIA	147
U.S.	147
ALTHEADX	148
AMBERGEN INC.	149
ASTRAZENECA PLC	149
ATOSSA GENETICS INC.	149
BIOTIME	150
CCC DIAGNOSTICS LLC	150
CLARINET	151
DAKO	152
DAKO NORTH AMERICA	152
EISAI INC. (HEADQUARTERS)	152
EUTROPICS PHARMACEUTICALS	153
FLUXION BIOSCIENCES	153
GENENTECH	153
GENOMIC HEALTH	154
GLAXOSMITHKLINE	154
LIFE TECHNOLOGIES	154
MDXHEALTH	155
MERCK AND COMPANY INC.	155
MYRIAD GENETICS	155
NANOSTRING TECHNOLOGIES	156
NEKTAR	156
PFIZER	156
PHIGENIX	157
RUBICON GENOMICS	157
SANOFI US	157
VENTANA MEDICAL SYSTEMS INC.	157
CHAPTER 10 DEVELOPMENTS AND COLLABORATIONS	160



<b>TOPIC</b>	<b>PAGE NO.</b>
CURRENT DEVELOPMENTS AND FUTURE	160
COMMERCIAL OPPORTUNITIES FOR CANCER BIOMARKER BASED DIAGNOSTIC TESTS	160
<i>TABLE 101 RESULTS OF A SURVEY BY MEDCO AND THE AMERICAN MEDICAL ASSOCIATION, 2009</i>	160
Breast Cancer Drugs and Patent Expiry: Roche Protects Breast-Cancer Drug Herceptin	161
RECENT BREAST CANCER TEST APPROVALS	161
FDA-Approved Use of Breast Cancer Assay on BenchMark ULTRA	161
Breast Cancer Tests	162
Oncotype DX	162
RECENT DEVELOPMENTS	163
BioTime: Development of the Novel Pan-Cancer Diagnostic Product PanC-Dx	163
Rubicon Genomics and Agendia Partner for Development of Breast Cancer Diagnostics	164
Abbott and Merck Partner to Evaluate Use of FISH-Based Companion Diagnostics	164
AltheaDx Partnering with Compendia Bioscience	164
GE Makes Investment in NanoString Technologies	165
Aeterna Zentaris Taps Ventana for Companion Diagnostic	165
MDxHealth Closes Agreement with Pfizer to Identify a Predictive Biomarker for PARP Inhibitor Therapies	166
FDA Grants Roche's Pertuzumab Priority Review	166
ALLIANCES	167
BREAST CANCER DRUG AND DIAGNOSTIC PATENT LANDSCAPE	167
Breast Cancer Drugs and Patent Expiry	167
Breast Cancer Predictive Diagnostic Patents	167
RECENT PATENT-RELATED ACTIVITY	168
"Who Owns Patients' Genes?" and Patent Issues	168
Myriad Gene Patent Ruling	168
New Breast Cancer Patent Awarded to Phigenix	169
Galena Biopharma Strengthens NeuVax Intellectual Property Position	169
CONCLUSIONS	170
CHAPTER 11 REFERENCES	172

## LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, THROUGH 2016 (\$ MILLIONS)	6
TABLE 1 POSSIBLE SIGNS OF BREAST CANCER	10
TABLE 2 DIAGNOSTIC MAMMOGRAM FOR BREAST CANCER	11
TABLE 3 BREAST CANCER GRADES	15
TABLE 4 BIOPSY OR SURGERY SAMPLE TESTING	16
TABLE 5 TESTS USED TO EVALUATE DIFFERENT GENE SETS	17
TABLE 6 IMAGING TESTS THAT DETERMINE IF BREAST CANCER HAS SPREAD	18
TABLE 7 HER2 TESTING AND VARIATIONS	19
TABLE 8 GUIDELINES FOR EARLY DETECTION OF BREAST CANCER IN AVERAGE RISK, ASYMPTOMATIC WOMEN	25
TABLE 9 BREAST CANCER SCREENING RECOMMENDATIONS BY THE USPSTF	26
TABLE 10 BREAST CANCER PROGNOSTIC FACTORS	30
TABLE 11 BREAST CANCER PREDICTIVE FACTORS	30
TABLE 12 RECURRENCE RATES AT FIVE YEARS IN PATIENTS WITH LYMPH NODES THAT ARE POSITIVE FOR CANCER (%)	31
TABLE 13 FIVE-YEAR SURVIVAL RATES CORRELATED WITH TUMOR STAGE (%)	31
TABLE 14 PREDICTIVE DIAGNOSTIC FEATURES	32
TABLE 15 CURRENT BIOMARKER TECHNOLOGIES	34
TABLE 16 BIOMARKER USES	35
TABLE 17 MAJOR ISSUES AND CHALLENGES	36
TABLE 18 PHARMACOGENOMICS TESTS IN USE	39
TABLE 19 BIOMARKERS FOR DRUG LABELS BASED ON SPECIFIC USE	40
TABLE 20 CANCER BIOMARKERS FOR FDA-MANDATED TESTING PRIOR TO DRUG USE	40
TABLE 21 CLINICALLY RELEVANT BIOMARKERS	40
TABLE 22 APPROVED COMPANION DIAGNOSTICS, 2011	41
TABLE 23 REGULATORY APPROVAL OF THE DIAGNOSTICS PATHWAY	44
TABLE 24 APPROVED CANCER DRUGS, 2011	47
TABLE 25 FACTORS INFLUENCING THE CHOICE OF A DIAGNOSTICS PARTNER	48
TABLE 26 SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS SUMMARY STAGE SYSTEM FOR BREAST CANCER	52
TABLE 27 MAIN TYPES OF BREAST CANCER	52
TABLE 28 BREAST CANCER EVALUATION TESTS	55
TABLE 29 TREATMENT PLAN	56
TABLE 30 HORMONE THERAPY	57
TABLE 31 CANCER STAGES	57
TABLE 32 RISK FACTORS OF RECURRENCE AFTER SUCCESSFUL TREATMENT FOR BREAST CANCER	58
TABLE 33 BREAST CANCER PREVENTION MEASURES	59
TABLE 34 AMERICAN CANCER SOCIETY'S DIETARY GUIDELINES FOR CANCER PREVENTION	59
TABLE 35 BREAST CANCER INCIDENCE AND MORTALITY GLOBALLY, 2008 (THOUSANDS)	63
TABLE 36 ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2010-2016	65
TABLE 37 NEW BREAST CANCER CASES BY GEOGRAPHIC REGION, 2009 (THOUSANDS/%)	66
TABLE 38 EFFECTIVE EDUCATION AND SCREENING ADVANTAGES IN THE U.K. AND THE U.S. (CASES PER DAY)	67
TABLE 39 CRUDE AND EUROPEAN AGE-STANDARDIZED BREAST CANCER INCIDENCE RATES PER 100,000 POPULATIONS IN THE U.K., 2008	68
TABLE 40 U.K. ESTIMATED INCIDENCE OF BREAST CANCER, 2010-2016 (THOUSANDS)	68

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 41 GERMAN ESTIMATED INCIDENCE OF BREAST CANCER AND PROJECTIONS, 2010-2016 (THOUSANDS)	69
TABLE 42 CHINESE ESTIMATED INCIDENCE OF BREAST CANCER, 2008-2016 (THOUSANDS)	71
TABLE 43 INDIA ESTIMATED INCIDENCE OF BREAST CANCER, 2008-2016 (THOUSANDS)	72
TABLE 44 JAPAN ESTIMATED INCIDENCE OF BREAST CANCER, 2010 (THOUSANDS)	73
TABLE 45 FIVE-YEAR SURVIVAL FOR BREAST CANCER (%)	74
TABLE 46 BREAST CANCER FIVE-YEAR SURVIVAL BY CANCER STAGE (%)	75
TABLE 47 U.S. ESTIMATED INCIDENCE OF BREAST CANCER, 2010-2016 (THOUSANDS)	77
TABLE 48 U.S. ESTIMATED NEW FEMALE BREAST CANCER CASES AND DEATHS BY AGE, 2011 (THOUSANDS)	78
TABLE 49 U.S. ESTIMATED INCIDENCE OF BREAST CANCER, 2012 (THOUSANDS)	79
TABLE 50 COMPARISON OF BREAST CANCER INCIDENCE AND DEATH IN MEN AND WOMEN, 2012	79
TABLE 51 ESTIMATED BREAST CANCER INCIDENCE, 2004-2008, AND MORTALITY, 2003-2007 (THOUSANDS)	81
TABLE 52 BREAST CANCER ESTIMATES IN ASIAN WOMEN, INCIDENCE, 2004-2008, AND MORTALITY, 2003-2007 (PER 100,000)	81
TABLE 53 ESTIMATED BREAST CANCER INCIDENCE IN HISPANIC AND LATINA WOMEN, 2004-2008, AND MORTALITY, 2003-2007 (PER 100,000)	82
TABLE 54 BREAST CANCER RISK WITH AGE	83
TABLE 55 U.S. RATES, TRENDS AND CAUSE-SPECIFIC SURVIVAL FOR FEMALE BREAST CANCER PATIENTS BY RACE OR ETHNICITY, 2001-2007	83
TABLE 56 RELATIVE CANCER SURVIVAL IN WOMEN	86
TABLE 57 CANADA ESTIMATED NUMBER OF NEW BREAST CANCER CASES IN FEMALES BY AGE, 2010 (THOUSANDS)	89
TABLE 58 AUSTRALIA PROJECTED NEW CASES OF BREAST CANCER, 2011-2021	90
TABLE 59 APPROVED ONCOLOGY DRUGS, 2012	92
TABLE 60 APPROVED ONCOLOGY DRUGS, 2011	93
TABLE 61 APPROVED ONCOLOGY DRUGS, 2010	93
TABLE 62 DRUGS APPROVED FOR BREAST CANCER	97
TABLE 63 HORMONE THERAPY FOR BREAST CANCER	98
TABLE 64 AROMATASE INHIBITORS FOR TREATING BREAST CANCER	99
TABLE 65 CHEMOTHERAPY DRUGS FOR TREATING BREAST CANCER	99
TABLE 66 COMMONLY USED COMBINATIONS	99
TABLE 67 MEDICINES TO CONTROL AND PREVENT NAUSEA AND VOMITING	100
TABLE 68 MARKET FOR TARGETED CANCER DRUGS, 2008 AND 2016 (\$ MILLIONS)	100
TABLE 69 TARGETED THERAPUTICS FOR BREAST CANCER	102
TABLE 70 GLOBAL PHARMACEUTICAL SALES, THROUGH 2016 (\$ MILLIONS)	103
TABLE 71 BREAST CANCER THERAPY SALES, THROUGH 2016 (\$ MILLIONS)	106
TABLE 72 BREAST CANCER DRUG MARKET, 2010 AND 2016 (\$ MILLIONS)	106
TABLE 73 AROMATASE INHIBITORS MARKET, 2010 AND 2016 (\$ MILLIONS)	107
TABLE 74 BREAST CANCER TARGETED THERAPIES, 2010 AND 2011 (\$ MILLIONS)	108
TABLE 75 ROCHE SALES COMPARED TO THE GLOBAL MARKET, 2010 (\$ MILLIONS/%)	108
TABLE 76 XELODA SALES, 2010 AND 2011 (\$ MILLIONS)	109
TABLE 77 ROCHE-SALES VERSUS THE GLOBAL MARKET, 2011 (\$ MILLIONS/%)	110
TABLE 78 EXPECTED SALES FOR PERTUZUMAB, 2016 (\$ MILLIONS)	111
TABLE 79 CANCER THERAPY SALES, 2008 AND 2018 (\$ MILLIONS)	112
TABLE 80 AUSTRALIA TARGETED CANCER THERAPY SALES, 2008 AND 2018 (\$ MILLIONS)	112
TABLE 81 ANTINEOPLASTIC MABS MARKET, 2008 AND 2014 (\$ MILLIONS)	116

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 82 U.S. PERSONALIZED MEDICINE MARKET, THROUGH 2016 (\$ MILLIONS)	117
TABLE 83 U.S. PERSONALIZED MEDICINE DIAGNOSTIC TESTS AND TARGETED THERAPIES MARKET, THROUGH 2016 (\$ MILLIONS)	118
TABLE 84 GLOBAL MOLECULAR DIAGNOSTICS MARKET, THROUGH 2016 (\$MILLIONS)	119
TABLE 85 GLOBAL IVD MARKET, THROUGH 2016 (\$MILLIONS)	121
TABLE 86 NEXT-GENERATION CANCER DIAGNOSTIC PRODUCTS BY TYPE, THROUGH 2016 (\$ MILLIONS)	122
TABLE 87 ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2010-2016 (\$ THOUSANDS)	123
TABLE 88 GLOBAL INCIDENCE OF ESTROGEN RECEPTOR POSITIVE BREAST CANCER CASES, 2010-2016 (\$ THOUSANDS)	124
TABLE 89 PREDICTIVE TECHNOLOGY	128
TABLE 90 BREAST CANCER DIAGNOSTIC TEST COSTS	130
TABLE 91 GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC TECHNOLOGIES, THROUGH 2016 (\$ MILLIONS)	131
TABLE 92 IHC AND FISH-BASED BREAST CANCER TESTING SALES, THROUGH 2016 (\$ MILLIONS)	132
TABLE 93 FDA-APPROVED COMMERCIAL KITS	133
TABLE 94 FDA-APPROVED FISH ANALYSIS TESTS	135
TABLE 95 ROCHE SALES BY DIVISION, 2010 (\$ MILLIONS)	137
TABLE 96 ROCHE COMPANION DIAGNOSTICS CURRENTLY ON THE MARKET OR IN LATE DEVELOPMENT FOR BREAST CANCER	137
TABLE 97 GENOMIC MARKET LEADERS	138
TABLE 98 GENOMIC TESTING MARKET FOR BREAST CANCER, THROUGH 2016 (\$ MILLIONS)	139
TABLE 99 ONCOTYPE DX SALES, THROUGH 2016 (\$ MILLIONS)	140
TABLE 100 QUANTITATIVE FLUORESCENCE DIAGNOSTIC TESTING MARKET FOR BREAST CANCER, THROUGH 2016 (\$ MILLIONS)	142
TABLE 101 RESULTS OF A SURVEY BY MEDCO AND THE AMERICAN MEDICAL ASSOCIATION, 2009	160

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, 2010-2016 (\$ MILLIONS)	6
FIGURE 1 GLOBAL BREAST CANCER INCIDENCE AND MORTALITY, 2008 (THOUSANDS)	63
FIGURE 2 ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2010-2016	65
FIGURE 3 U.K. ESTIMATED INCIDENCE OF BREAST CANCER, 2010-2016 (THOUSANDS)	68
FIGURE 4 GERMAN ESTIMATED INCIDENCE OF BREAST CANCER, 2010-2016 (THOUSANDS)	70
FIGURE 5 CHINESE ESTIMATED INCIDENCE OF BREAST CANCER, 2010-2016 (THOUSANDS)	71
FIGURE 6 INDIA ESTIMATED INCIDENCE OF BREAST CANCER, 2010-2016 (THOUSANDS)	72
FIGURE 7 U.S. ESTIMATED INCIDENCE OF BREAST CANCER, 2010-2016 (THOUSANDS)	77
FIGURE 8 GLOBAL PHARMACEUTICAL SALES, 2010-2016 (\$ MILLIONS)	103
FIGURE 9 BREAST CANCER THERAPY SALES, 2010-2016 (\$ MILLIONS)	106
FIGURE 10 BREAST CANCER DRUG MARKET, 2010 AND 2016 (\$ MILLIONS)	107
FIGURE 11 U.S. PERSONALIZED MEDICINE MARKET, 2010-2016 (\$ MILLIONS)	117
FIGURE 12 U.S. PERSONALIZED MEDICINE DIAGNOSTIC TESTS AND TARGETED THERAPIES MARKET, 2010-2016 (\$ MILLIONS)	118
FIGURE 13 NEXT-GENERATION CANCER DIAGNOSTIC PRODUCTS BY TYPE, 2010-2016 (\$ MILLIONS)	122
FIGURE 14 GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC TECHNOLOGIES, 2010-2016 (\$ MILLIONS)	131
FIGURE 15 IHC AND FISH-BASED BREAST CANCER TESTING SALES, 2010-2012 (\$ MILLIONS)	132
FIGURE 16 GENOMIC TESTING MARKET FOR BREAST CANCER, 2010-2016 (\$ MILLIONS)	139
FIGURE 17 QUANTITATIVE FLUORESCENCE DIAGNOSTIC TESTING MARKET FOR BREAST CANCER, 2010-2016 (\$ MILLIONS)	142